ACAD
Price
$14.73
Change
+$0.16 (+1.10%)
Updated
Apr 17 closing price
Capitalization
2.46B
23 days until earnings call
TVRD
Price
$17.04
Change
-$1.21 (-6.63%)
Updated
Apr 17 closing price
Capitalization
159.41M
Ad is loading...

ACAD vs TVRD

Header iconACAD vs TVRD Comparison
Open Charts ACAD vs TVRDBanner chart's image
ACADIA Pharmaceuticals
Price$14.73
Change+$0.16 (+1.10%)
Volume$1.21M
Capitalization2.46B
Tvardi Therapeutics
Price$17.04
Change-$1.21 (-6.63%)
Volume$38.25K
Capitalization159.41M
ACAD vs TVRD Comparison Chart
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TVRD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. TVRD commentary
Apr 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and TVRD is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 20, 2025
Stock price -- (ACAD: $14.73 vs. TVRD: $17.04)
Brand notoriety: ACAD and TVRD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 68% vs. TVRD: 169%
Market capitalization -- ACAD: $2.46B vs. TVRD: $159.41M
ACAD [@Biotechnology] is valued at $2.46B. TVRD’s [@Biotechnology] market capitalization is $159.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileTVRD’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • TVRD’s FA Score: 1 green, 4 red.
According to our system of comparison, TVRD is a better buy in the long-term than ACAD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 4 TA indicator(s) are bullish while TVRD’s TA Score has 5 bullish TA indicator(s).

  • ACAD’s TA Score: 4 bullish, 4 bearish.
  • TVRD’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, TVRD is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а +4.39% price change this week, while TVRD (@Biotechnology) price change was +250.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.03%. For the same industry, the average monthly price growth was -13.25%, and the average quarterly price growth was -24.49%.

Reported Earning Dates

ACAD is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+7.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($2.46B) has a higher market cap than TVRD($159M). TVRD YTD gains are higher at: 178.417 vs. ACAD (-19.728).
ACADTVRDACAD / TVRD
Capitalization2.46B159M1,545%
EBITDA100MN/A-
Gain YTD-19.728178.417-11%
P/E Ratio10.83N/A-
Revenue958MN/A-
Total Cash756MN/A-
Total Debt52MN/A-
FUNDAMENTALS RATINGS
ACAD vs TVRD: Fundamental Ratings
ACAD
TVRD
OUTLOOK RATING
1..100
152
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
5
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
25100
PRICE GROWTH RATING
1..100
7650
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TVRD's Valuation (5) in the null industry is somewhat better than the same rating for ACAD (60) in the Biotechnology industry. This means that TVRD’s stock grew somewhat faster than ACAD’s over the last 12 months.

TVRD's Profit vs Risk Rating (100) in the null industry is in the same range as ACAD (100) in the Biotechnology industry. This means that TVRD’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's SMR Rating (25) in the Biotechnology industry is significantly better than the same rating for TVRD (100) in the null industry. This means that ACAD’s stock grew significantly faster than TVRD’s over the last 12 months.

TVRD's Price Growth Rating (50) in the null industry is in the same range as ACAD (76) in the Biotechnology industry. This means that TVRD’s stock grew similarly to ACAD’s over the last 12 months.

TVRD's P/E Growth Rating (100) in the null industry is in the same range as ACAD (100) in the Biotechnology industry. This means that TVRD’s stock grew similarly to ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADTVRD
RSI
ODDS (%)
Bullish Trend 3 days ago
67%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 3 days ago
67%
Bullish Trend 3 days ago
83%
MACD
ODDS (%)
Bearish Trend 3 days ago
62%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 5 days ago
73%
N/A
Declines
ODDS (%)
Bearish Trend 12 days ago
72%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
67%
View a ticker or compare two or three
Ad is loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TVRD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.780.53
+2.02%
GameStop Corp
AAPL196.982.71
+1.39%
Apple
SPY526.410.75
+0.14%
SPDR® S&P 500® ETF
TSLA241.37-0.18
-0.07%
Tesla
BTC.X84450.805000-444.945300
-0.52%
Bitcoin cryptocurrency

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with RGNX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+1.10%
RGNX - ACAD
50%
Loosely correlated
-3.57%
XNCR - ACAD
44%
Loosely correlated
+1.89%
HRTX - ACAD
44%
Loosely correlated
N/A
RCKT - ACAD
43%
Loosely correlated
+2.93%
KOD - ACAD
41%
Loosely correlated
+20.34%
More

TVRD and

Correlation & Price change

A.I.dvisor indicates that over the last year, TVRD has been loosely correlated with COEP. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if TVRD jumps, then COEP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TVRD
1D Price
Change %
TVRD100%
-6.63%
COEP - TVRD
41%
Loosely correlated
+7.82%
APM - TVRD
40%
Loosely correlated
-9.14%
NRXP - TVRD
25%
Poorly correlated
N/A
VSTM - TVRD
23%
Poorly correlated
+15.73%
ACAD - TVRD
22%
Poorly correlated
+1.10%
More